XML 41 R34.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Schedule of Segment Information, Including Significant Segment Expenses | The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the three months ended March 31, 2025 and 2024 (in thousands):
|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
MRD: |  |  |  |  |  |
Revenue |  | $ | 43,721 |  |  | $ | 32,626 |
Less: |  |  |  |  |  |
Cost of revenue |  |  | 15,885 |  |  |  | 15,921 |
Research and development |  |  | 9,159 |  |  |  | 12,924 |
Sales and marketing |  |  | 21,413 |  |  |  | 20,385 |
General and administrative |  |  | 9,502 |  |  |  | 10,656 |
Add back: |  |  |  |  |  |
Items to reconcile net loss to Adjusted EBITDA(1) |  |  | 8,127 |  |  |  | 10,001 |
Adjusted EBITDA(1) |  | $ | (4,111 | ) |  | $ | (17,259 | )
Immune Medicine: |  |  |  |  |  |
Revenue |  | $ | 8,722 |  |  | $ | 9,247 |
Less: |  |  |  |  |  |
Research and development |  |  | 15,044 |  |  |  | 17,321 |
Other segment items(2) |  |  | 5,159 |  |  |  | 6,519 |
Add back: |  |  |  |  |  |
Items to reconcile net loss to Adjusted EBITDA(1) |  |  | 6,035 |  |  |  | 7,666 |
Adjusted EBITDA(1) |  | $ | (5,446 | ) |  | $ | (6,927 | )
|  | Three Months Ended March 31, 2025 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Reconciliation of Adjusted EBITDA(1) to Net Loss: |  |  |  |  |  |  |  |  |  |  |  |
Adjusted EBITDA(1) |  | $ | (4,111 | ) |  | $ | (5,446 | ) |  | $ | (3,191 | ) |  | $ | (12,748 | )
Share-based compensation expense(3) |  |  | (5,464 | ) |  |  | (4,393 | ) |  |  | (2,290 | ) |  |  | (12,147 | )
Depreciation and amortization expense |  |  | (2,663 | ) |  |  | (1,642 | ) |  |  | (426 | ) |  |  | (4,731 | )
Interest expense(4) |  |  | — |  |  |  | — |  |  |  | (2,905 | ) |  |  | (2,905 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | 2,679 |  |  |  | 2,679 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  |  |  |  |  |  |  |  |  |  | (29,852 | )
Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  | 22 |
Net loss |  |  |  |  |  |  |  |  |  |  | $ | (29,830 | )
|  | Three Months Ended March 31, 2024 |
|  | MRD |  |  | Immune Medicine |  |  | Unallocated Corporate |  |  | Total |
Reconciliation of Adjusted EBITDA(1) to Net Loss: |  |  |  |  |  |  |  |  |  |  |  |
Adjusted EBITDA(1) |  | $ | (17,259 | ) |  | $ | (6,927 | ) |  | $ | (3,994 | ) |  | $ | (28,180 | )
Share-based compensation expense(3) |  |  | (6,833 | ) |  |  | (5,007 | ) |  |  | (2,458 | ) |  |  | (14,298 | )
Restructuring expense(5) |  |  | (467 | ) |  |  | (577 | ) |  |  | — |  |  |  | (1,044 | )
Depreciation and amortization expense |  |  | (2,701 | ) |  |  | (2,082 | ) |  |  | (431 | ) |  |  | (5,214 | )
Interest expense(4) |  |  | — |  |  |  | — |  |  |  | (2,993 | ) |  |  | (2,993 | )
Interest and other income, net |  |  | — |  |  |  | — |  |  |  | 4,222 |  |  |  | 4,222 |
Net loss attributable to Adaptive Biotechnologies Corporation |  |  |  |  |  |  |  |  |  |  |  | (47,507 | )
Net loss attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  | (26 | )
Net loss |  |  |  |  |  |  |  |  |  |  | $ | (47,533 | )
(1) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management. (2) Includes all Immune Medicine operating expenses, other than research and development expenses. (3) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense. (4) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement. (5) Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructuring for details on our restructuring expense.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration